Mafalda M Dias1, Ross A McKinnon, Michael J Sorich. 1. University of South Australia, Division of Health Sciences, School of Pharmacy & Medical Sciences, GPO Box 2471, Adelaide, South Australia 5001, Australia.
Abstract
AIM: Pre-emptive irinotecan dose reduction for UGT1A1*28 homozygotes may result in reduced risk of severe neutropenia and diarrhea. However, clinical utility and cost-effectiveness are dependent upon such a dose reduction not impacting irinotecan efficacy. Whether UGT1A1*28 genotype is associated with irinotecan response therefore is an important gap in existing knowledge to inform clinical utility. MATERIALS & METHODS: A systematic review and meta-analysis was performed to analyze the difference in objective response rate (ORR) between irinotecan-administered cancer patients with different UGT1A1*28 genotypes: *28/*28 (homozygous variant), *1/*28 (heterozygous variant) or *1/*1 (wild-type). The effect of irinotecan dose on the association between UGT1A1*28 and ORR was also assessed. RESULTS: Differences in ORR for either of the genotype comparisons, *28/*28 versus *1/*1 and *1/*28 versus *1/*1, were not statistically significant. Irinotecan dose also did not impact upon ORR differences between UGT1A1 genotype groups. CONCLUSION: An individual's response to irinotecan is unlikely to be affected by UGT1A1*28 status.
AIM: Pre-emptive irinotecan dose reduction for UGT1A1*28 homozygotes may result in reduced risk of severe neutropenia and diarrhea. However, clinical utility and cost-effectiveness are dependent upon such a dose reduction not impacting irinotecan efficacy. Whether UGT1A1*28 genotype is associated with irinotecan response therefore is an important gap in existing knowledge to inform clinical utility. MATERIALS & METHODS: A systematic review and meta-analysis was performed to analyze the difference in objective response rate (ORR) between irinotecan-administered cancerpatients with different UGT1A1*28 genotypes: *28/*28 (homozygous variant), *1/*28 (heterozygous variant) or *1/*1 (wild-type). The effect of irinotecan dose on the association between UGT1A1*28 and ORR was also assessed. RESULTS: Differences in ORR for either of the genotype comparisons, *28/*28 versus *1/*1 and *1/*28 versus *1/*1, were not statistically significant. Irinotecan dose also did not impact upon ORR differences between UGT1A1 genotype groups. CONCLUSION: An individual's response to irinotecan is unlikely to be affected by UGT1A1*28 status.
Authors: Gustaw Lech; Robert Słotwiński; Maciej Słodkowski; Ireneusz Wojciech Krasnodębski Journal: World J Gastroenterol Date: 2016-02-07 Impact factor: 5.742
Authors: Michael Michael; Winston Liauw; Sue-Anne McLachlan; Emma Link; Annetta Matera; Michael Thompson; Michael Jefford; Rod J Hicks; Carleen Cullinane; Athena Hatzimihalis; Ian G Campbell; Simone Rowley; Phillip J Beale; Christos S Karapetis; Timothy Price; Mathew E Burge Journal: Cancer Chemother Pharmacol Date: 2021-03-23 Impact factor: 3.333
Authors: S Chen; I Laverdiere; A Tourancheau; D Jonker; F Couture; E Cecchin; L Villeneuve; M Harvey; M H Court; F Innocenti; G Toffoli; E Lévesque; C Guillemette Journal: Pharmacogenomics J Date: 2015-03-17 Impact factor: 3.550
Authors: Otito F Iwuchukwu; QiPing Feng; Wei-Qi Wei; Lan Jiang; Min Jiang; Hua Xu; Joshua C Denny; Russell A Wilke; Ronald M Krauss; Dan M Roden; C Michael Stein Journal: Pharmacogenomics Date: 2014-11 Impact factor: 2.533
Authors: Angela Roco; Luis Quiñones; José A G Agúndez; Elena García-Martín; Valentina Squicciarini; Carla Miranda; Joselyn Garay; Nancy Farfán; Iván Saavedra; Dante Cáceres; Carol Ibarra; Nelson Varela Journal: Front Genet Date: 2012-11-02 Impact factor: 4.599